OmniAbOABI +1.47%71 Beneish M-Score is -2.18 as of Jul. 04, 2026. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 829 Biotechnology companies, OmniAb ranks worse than 56.09% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.18 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for OmniAb's Beneish M-Score or its related term are showing as below:
OABI'
s Beneish M-Score Range Over the Past 10 Years
Min: -4.45 Med: -2.61 Max: 1.74
Current: -2.18
During the past 7 years, the highest Beneish M-Score of OmniAb was 1.74. The lowest was -4.45. And the median was -2.61.
OmniAb Beneish M-Score Related Terms
OmniAb Beneish M-Score Historical Data
* Premium members only.
The historical data trend for OmniAb's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OABI vs VNDA, AVIR, UPB: Beneish M-Score Comparison
For the Biotechnology subindustry, OmniAb's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OmniAb Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OmniAb's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where OmniAb's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of OmniAb for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.8031
+
0.528 * 1.0109
+
0.404 * 0.9661
+
0.892 * 1.0821
+
0.115 * 0.8423
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.851
+
4.679 * -0.108565
-
0.327 * 1.0157
=
-2.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(23.377 / (23.377 + 31.95))
/
(24.225 / (24.225 + 24.07))
=
0.422524
/
0.501605
=
0.8423
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-54.286 - 3.091
-
-25.497)
/
293.65
=
-0.108565
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
OmniAb has a M-score of -2.18 suggests that the company is unlikely to be a manipulator.
OmniAb (OABI) has a Beneish M-Score of -2.18 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on OmniAb and its competitors. According to the industry distribution chart, OmniAb ranks #465 out of 829 companies in the Biotechnology industry, placing it in the top 56.1%.
Is OmniAb's Beneish M-Score too high?
OmniAb's current Beneish M-Score is -2.18. Based on the distribution chart, OmniAb ranks #465 out of 829 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Beneish M-Score compare to VNDA and AVIR?
According to the Biotechnology industry distribution chart, OmniAb ranks #465 out of 829 companies for Beneish M-Score. This places OmniAb in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on OmniAb and its competitors. OmniAb's current Beneish M-Score is -2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current Beneish M-Score is -2.18. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For OmniAb (OABI), the current Beneish M-Score is -2.18 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OmniAb (OABI) Overvalued in 2026?
Based on GuruFocus' analysis, OmniAb stock appears to be overvalued.
The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27.
GuruFocus considers OmniAb to be Fairly Valued.
Key valuation signals for OABI:
Beneish M-Score: -2.18
GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
71GF Score
Get the complete analysis for OABI
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OABI has been successfully added to your 
